Mylan offers concessions to address EU concerns about Pfizer deal

Stock Market
© Reuters. A logo for Pfizer is displayed on a monitor on the floor at the NYSE in New York © Reuters. A logo for Pfizer is displayed on a monitor on the floor at the NYSE in New York

BRUSSELS (Reuters) – Generic drugmaker Mylan NV (O:) has offered concessions to address European Union antitrust concerns about its bid for Pfizer ‘s (N:) off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday.

U.S. drugmaker Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines.

The European Commission set an April 22 deadline for its decision after Mylan put in its offer on March 27.

In line with its policy, the EU competition watchdog did not provide details of the concessions. It will now seek feedback from rivals and customers before deciding whether to accept the offer, demand more or open a full-scale investigation.

Companies typically have to sell assets or agree to licensing deals to allay regulatory concerns.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Let’s block ads! (Why?)

Stock Market News

Leave a Reply

Your email address will not be published. Required fields are marked *